Literature DB >> 19863171

Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments.

Josée M Zijlstra1, Ronald Boellaard, Otto S Hoekstra.   

Abstract

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is being used much more for response monitoring in multi-center studies. By visual assessment, positron emission tomography (PET) will be scored as negative or positive according to the abnormal 18F-fluorodeoxyglucose (FDG) uptake at previously involved sites. However, a gray-zone does exist especially in interim-PET scans. Besides visual inspection, semi-quantitative analyses using standardized uptake values (SUVs) allow for an objective assessment of treatment response, thereby eliminating observer variation and providing the opportunity to reduce the gray-zone by adding the quantitative power of PET. However, comparison of SUV results is often hampered by the wide variability in methodology of data acquisition, image reconstruction, and data analysis procedures. In the Netherlands, a protocol for standardization and quantification of FDG-PET whole body studies has been defined for the accurate use of SUVs in FDG-PET multi-center studies. Here, we report a summary of the main issues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863171     DOI: 10.3109/10428190903308049

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Variability in PET quantitation within a multicenter consortium.

Authors:  Frederic H Fahey; Paul E Kinahan; Robert K Doot; Mehmet Kocak; Harold Thurston; Tina Young Poussaint
Journal:  Med Phys       Date:  2010-07       Impact factor: 4.071

Review 2.  PET/CT in malignant lymphoma: basic information, clinical application, and proposal.

Authors:  Ukihide Tateishi
Journal:  Int J Hematol       Date:  2013-09-25       Impact factor: 2.490

Review 3.  Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm.

Authors:  Ian N Fleming; Fiona J Gilbert; Ken A Miles; David Cameron
Journal:  Cancer Imaging       Date:  2010-07-06       Impact factor: 3.909

Review 4.  The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.

Authors:  Monica Coughlan; Rebecca Elstrom
Journal:  Cancer Imaging       Date:  2014-11-29       Impact factor: 3.909

5.  Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients.

Authors:  Monique Aj van Eijndhoven; Josée M Zijlstra; Nils J Groenewegen; Esther Ee Drees; Stuart van Niele; S Rubina Baglio; Danijela Koppers-Lalic; Hans van der Voorn; Sten Fwm Libregts; Marca Hm Wauben; Renee X de Menezes; Jan Rt van Weering; Rienk Nieuwland; Lydia Visser; Anke van den Berg; Daphne de Jong; D Michiel Pegtel
Journal:  JCI Insight       Date:  2016-11-17

Review 6.  The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials.

Authors:  Stephane Chauvie; Fabrizio Bergesio
Journal:  Biomedicines       Date:  2016-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.